Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Delos Santos

P1.01-16 First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 Positive NSCLC: A Network Meta-Analysis of Randomized Trials

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn34 - Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-Squamous NSCLC – A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA04.05 Outcomes in NSCLC Patients Treated With First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Immunotherapy
OncologyAllergyImmunology
2019English

Cost Effectiveness of PD-L1-Based Test-And-Treat Strategy With Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

PharmacoEconomics - Open
Health PolicyPharmacology
2019English

Meta-Analysis of Randomized Trials on First Line and Adjunctive Levetiracetam

Canadian Journal of Neurological Sciences
MedicineNeurology
2011English

Anti-Pd-1/Pd-L1 Antibody Versus Conventional Chemotherapy for Previously-Treated, Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy